Obesity: The Cause of Chronic Disease?

Obesity: The Cause of Chronic Disease?

One in three adults in North America is obese. Obesity leads to a range of chronic diseases, many of which can be avoided with proper weight management.

The obesity management market is expected to expand at a CAGR of 4.9% during the forecast period from 2024 to 2030. The overall market value is expected to grow to US$3.3 billion by 2030.

Among them, the elderly market is a key growth part of the market in both the short and long term. This is because the elderly population in developed countries continues to grow, and it is very easy for the elderly to gain significant body fat and lose muscle mass and functional abilities. Therefore, the need for obesity management to maintain health and extend life is very important, further driving market development.

Analysis of Relevant Factors Expected to Drive Market Development:

  • Increase in obesity
  • Increasing number of bariatric surgeries
  • Rising disposable income in developing economies
  • Sedentary lifestyle
  • Increased awareness of genetics and drug side effects linked to obesity

At the same time, there are also some challenges:

  • The high cost of surgery and medications; bariatric surgery is not reimbursed at a discounted rate in developing countries.
  • Strict government and institutional regulations on the safety of obesity management drugs and ongoing clinical trials have slowed the pace of drugs entering the market.
  • Potential for drug-induced cardiovascular disease or cancer.

Market Segmentation by Company

The overall market is relatively concentrated, with only a few leading companies participating in the competition. There are a large number of players in this market involved in the research and development of product innovations and the development of existing products.

  • Currax Pharmaceuticals LLC
  • Bayer AG
  • GlaxoSmithKline plc
  • AstraZeneca
  • Rhythm Pharmaceuticals, Inc
  • Novo Nordisk
  • Vivus
  • Pfizer Inc
  • Merck Sharp & Dohme Corp
  • F Hoffmann-La Roche Ltd
  • ......

In January 2018, H2-Pharma announced a collaboration with Cheplapharm Arzneimittel GmbH in January 2018 and re-launched XENICAL? 120 mg capsules through its newly formed branded division.

In February 2020, VIVUS, Inc. announced in February 2020 that its Korean marketing partner, Alvogen, had launched Qsymia in the Republic of Korea.

In June 2021, Novo Nordisk received FDA approval for Wegovy semaglutide injection in adults with at least one weight-related condition in June 2021.

Market Segmentation by Classification

  • Peripherally Acting Drugs
  • Centrally Acting Drugs

Market Segmentation by End-Users

  • Hospital Pharmacies
  • Retail Pharmacies

Key Benefits for Stakeholders

The report provides a quantitative analysis of the current Obesity Management market trends, estimations, and dynamics of the market size from 2024 to 2030 to identify the prevailing opportunities.

Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth Obesity Management market analysis and the market size and segmentation assist in determining the prevailing Obesity Management market opportunities.

The major countries in each region are mapped according to their revenue contribution to the market.

The market player positioning segment facilitates benchmarking and provides a clear understanding of the present position of the market players in the Obesity Management industry.

Related Market Research Reports:

2023 Global Obesity Management Market Analysis Report, Key Competitors, Market Effect Factors, Growth, And Forecast


要查看或添加评论,请登录

Market Monitor的更多文章

社区洞察

其他会员也浏览了